Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of DN1406131 in Healthy Adults

Trial Profile

A Phase I Study of DN1406131 in Healthy Adults

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs DN-1406131 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Jiangxi Qingfeng Pharmaceutical
  • Most Recent Events

    • 06 Sep 2018 According to Shanghai De Novo Pharmatech media release, the U.S. Food and Drug Adminiatrstion (FDA)'s approval of DN1406131's Investigational New Drug (IND) application in Jan 2018, Shanghai De Novo pharmatech Co., Ltd has received Clinical Trial Application (CTA) approval on May 29, 2018 from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with DN1406131.
    • 28 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top